Phase II study of dose-dense doxorubicin and docetaxel as neoadjuvant chemotherapy with G-CSF support in patients with large or locally advanced breast cancer

Clinical and Translational Oncology

Volumn 10, Issue 11, 2008, Pages 739-744

  García Mata, Jesús ^a   García Palomo, Andrés ^b   Calvo, Lourdes ^c   Mel, Ramón ^d   Cruz, Juan Jesús ^e,g   Ramos, Manuel ^f,g  

^a Hospital Santa Maria Nai   (Spain)

^b HOSPITAL DE LEÓN   (Spain)

^c HOSPITAL JUAN CANALEJO   (Spain)

^d HOSPITAL XERAL CALDE   (Spain)

^e HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^f Cent Oncol Reg   (Spain)

^g Complexo Hospitalario de Ourense   (Spain)

Author keywords

Anthracycline; Biweekly; Dose intensity; Primary chemotherapy; Taxanes

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; TAXOID;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; ASTHENIA; BREAST TUMOR; CARCINOMA; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG ERUPTION; FEMALE; HUMAN; MASTECTOMY; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; STOMATITIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ASTHENIA; BREAST NEOPLASMS; CARCINOMA; COMBINED MODALITY THERAPY; DOXORUBICIN; DRUG ERUPTIONS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MASTECTOMY; MIDDLE AGED; NEOADJUVANT THERAPY; NEUTROPENIA; PROSPECTIVE STUDIES; STOMATITIS; TAXOIDS;

EID: 59249084893     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-008-0280-z     Document Type: Article

References (24)

1. Parkin DM, Fernandez LM (2006) Use of statistics to assess the global burden of breast cancer. Breast J 12[Suppl 1]:S70-80
2. Fisher B, Bryant J, Wolmark N et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685
3. von Minckwitz G, Costa SD, Eiermann W et al (1999) Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J Clin Oncol 17:1999-2005
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717
5. Nabholtz JM, Falkson C, Campos D et al (2003) Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 21:968-975
6. Mackey JR, Paterson A, Dirix LY et al (2002) Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclo phos phamide (C) to FAC as first line che-motherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 21:35a
7. Martin M, Pienkowski T, Mackey J et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302-2313
8. Smith IC, Heys SD, Hutcheon AW et al (2002) Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20:1456-1466
9. Bear HD, Anderson S, Brown A et al (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21:4165-4174
10. Holmes FA, Rowinsky EK (2001) Pharmacokinetic profiles of doxorubicin in combination with taxanes. Semin Oncol 28:8-14
11. Valero V, Perez E, Dieras V (2001) Doxorubicin and taxane combination regimens for metastatic breast cancer: focus on cardiac effects. Semin Oncol 28:15-23
12. Norton L (1997) Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol 24:S10-13-S10-10
13. Gianni L, Mariani G, Mariani P (2004) Role of dose in the treatment of breast cancer. Ann Oncol 15[Suppl 4]:iv31-35
14. Citron ML, Berry DA, Cirrincione C et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439
15. Keith B, Hall R, Scholnik A (2004) Improved outcome with dose-dense chemotherapy. J Clin Oncol 22:749; author reply 751-753
16. (1999) Common Toxicity Criteria, Version 2.0. National Cancer Institute, Cancer Therapy Evaluation Program, Bethesda, MD, pp 1-27
17. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
18. Evans TR, Yellowlees A, Foster E et al (2005) Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an Anglo-Celtic Cooperative Oncology Group study. J Clin Oncol 23:2988-2995
19. von Minckwitz G, Raab G, Caputo A et al (2005) Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 23:2676-2685
20. Miller KD, McCaskill-Stevens W, Sisk J et al (1999) Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol 17:3033-3037
21. Ganem G, Tubiana-Hulin M, Fumoleau P et al (2003) Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer. Ann Oncol 14:1623-1628
22. Han S, Kim SB, Kang SS et al (2006) A phase II study of neoadjuvant docetaxel plus doxorubicin (KBCS-01) in stage II, III breast cancer. Breast Cancer Res Treat 98:57-61
23. Cooper BW, Radivoyevitch T, Overmoyer BA et al (2006) Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer. Bre ast Cancer Res Treat 97:311-318
24. Swain SM, Sorace RA, Bagley CS et al (1987) Neo adjuvant chemotherapy in the combined mo-dality approach of locally advanced nonmetastatic breast cancer. Cancer Res 47:3889-3894